Gene-Based dosing study aims to make cancer drug safer

NCT ID NCT02680795

Completed Knowledge-focused Sponsor: Acrotech Biopharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug is processed. The goal was to gather information for safer dosing in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belinostat (Beleodaq)
What this could lead to: If successful, this study could help doctors understand how to dose belinostat more safely for patients with different genetic backgrounds.
What could go wrong: This is a very early, small study with only 17 participants, so results may not apply to all patients. The drug may still cause side effects regardless of gene type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES SOLID TUMORS

Contacts and locations

Locations

Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
John Wayne Cancer Institute @ Providence Saint John's Health Center

Santa Monica, California, 90404, United States
The Oncology Institute of Hope and Innovation

Whittier, California, 90603, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.